The global leadless pacemakers market size was valued at USD 842.37 million in 2024 and is projected to reach USD 1,622.87 million by 2033, registering a CAGR of 6.48% from 2025 to 2033. The rising prevalence of cardiac disorders and associated risk factors continues to drive the need for advanced device-based therapies.
According to an article published by Oxford Academic in January 2025, the global age-standardized prevalence of cardiovascular disease is estimated at approximately 7,179 cases per 100,000 people, highlighting the substantial and growing burden of cardiac conditions. This escalating prevalence has reinforced the need for innovative pacing technologies capable of managing rhythm disorders more effectively and with fewer complications.
Leadless pacemakers have gained prominence as a transformative solution, offering a minimally invasive alternative to traditional pacemakers by eliminating leads and surgical pockets. Over the past decade, these devices have become a well-established option, providing several clinical advantages. According to an NCBI article published in April 2025, leadless devices such as Micra and Aveir significantly reduce risks of complications including infections, electrode dislocation, pocket hematomas, pneumothorax, endocarditis, and venous obstruction.
Evidence from the Micra PAR registry, which tracked 1,809 patients over an average 51-month period, shows a five-year major complication rate of just 4.5%, with most complications occurring within the first month of implantation. Importantly, no infection cases required device removal, and system revisions were infrequent, typically related to device upgrades or battery depletion.
Order a free sample PDF of the Leadless Pacemakers Market Intelligence Study, published by Grand View Research.
Key Market Trends & Insights
- North America dominated the global market in 2024 with a revenue share of 60.04%.
- The U.S. held the largest share within North America.
- By chambers, the single-chamber segment held the largest share in 2024.
- By brands, the Micra VR and VR2 segment accounted for the highest market share in 2024.
- By end use, hospitals remained the leading segment in 2024.
Market Size & Forecast
- 2024 Market Size: USD 842.37 Million
- 2033 Projected Market Size: USD 1,622.87 Million
- CAGR (2025–2033): 6.48%
- Largest Market (2024): North America
- Fastest Growing Market (2024): Asia Pacific
Key Leadless Pacemakers Company Insights
Companies operating in the leadless pacemakers market are actively pursuing expansion strategies, technological advancements, and strategic partnerships to enhance their product reach and strengthen their market position. Leading players continue to focus on improving device longevity, safety, and clinical outcomes.
Key Leadless Pacemaker Companies
- Abbott
- Medtronic
- EBR Systems, Inc.
- Boston Scientific Corporation
- MicroPort Scientific Corporation
Explore Horizon Databook - The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The global leadless pacemakers market is anticipated to grow steadily through 2033, supported by rising cardiovascular disease prevalence and increasing demand for safer, more effective pacing options. Leadless pacemakers have demonstrated significant clinical advantages with lower complication rates and improved patient outcomes compared to traditional systems. With strong market dominance in North America and rapid expansion in Asia Pacific, technological innovation, strategic collaborations, and broader adoption in healthcare facilities are expected to continue driving the market’s upward trajectory.